Top

Published in:

Open Access 01-12-2003 | Review

Ovarian surface epithelium: family history and early events in ovarian cancer

Authors: Alice ST Wong, Nelly Auersperg

Published in: Reproductive Biology and Endocrinology | Issue 1/2003

Abstract

Ovarian cancer is the most common cause of death from gynecological cancers in the Western world. There are many genetic and environmental factors which can influence a woman's risk of getting ovarian cancer. A strong family history of breast or ovarian cancer is definitely one of the most important and best-defined epidemiological risk factors. This review evaluates current knowledge of hereditary ovarian cancer. Histologic, cytologic and molecular studies on the ovarian surface epithelium (OSE), which is the origin of ovarian epithelial carcinomas, from women with a strong family history for ovarian carcinomas or with a mutation in one of the two known cancer susceptibility genes – BRCA1 and BRCA2, provide a background to facilitate understanding of the early changes in ovarian carcinogenesis. This overview is followed by a discussion of recent hypotheses and research on two questions. First, is there a mutational hotspot of BRCA mutation for ovarian cancer? Second, why do mutations in BRCA1 and BRCA2, which are ubiquitously expressed genes that participate in general cellular activities, lead preferentially to breast and ovarian cancer?

Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et al.: Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. Am J Hum Genet. 2003, 72: 1117-1130. 10.1086/375033.PubMedCentralCrossRefPubMed

Boyd J: Hereditary ovarian cancer: What we know. Gynecol Oncol. 2003, 88: S8-S10. 10.1006/gyno.2002.6674.CrossRefPubMed

Lindblom A, Tannergard P, Werelius B, Nordenskjold M: Genetic mapping of a second locus predisposing to human nonpolyposis colorectal cancer. Nat Genet. 1993, 5: 279-282.CrossRefPubMed

Lynch HT, Lynch JF: Hereditary cancer: family history, diagnosis, molecular genetics, ecogenetics, and management strategies. Biochimie. 2002, 84: 3-17. 10.1016/S0300-9084(01)01363-3.CrossRefPubMed

Peltomaki P, Aaltonen L, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Green JS, Jass JR, Weber JL, Weber FS, et al.: Genetic mapping of a locus predisposing to human colorectal cancer. Science. 1993, 260: 810-812.CrossRefPubMed

Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994, 266: 66-71.CrossRefPubMed

Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, et al.: The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996, 12: 333-337.CrossRefPubMed

Welcsh PL, King MC: BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001, 10: 705-713. 10.1093/hmg/10.7.705.CrossRefPubMed

Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC: Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 2001, 22: 255-88. 10.1210/er.22.2.255.PubMed

10.

Gusberg SB, Deligdisch L: Ovarian dysplasia. A study of identical twins. Cancer. 1984, 54: 1-4.CrossRefPubMed

11.

Deligdisch L, Gil J: Characterization of ovarian dysplasia by interactive morphometry. Cancer. 1989, 63: 748-755.CrossRefPubMed

12.

Plaxe SC, Deligdisch L, Dottino PR, Cohen CJ: Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian carcinoma. Gynecol Oncol. 1990, 38: 367-372.CrossRefPubMed

13.

Salazar H, Godwin AK, Daly MB, Laub PB, Hogan WM, Rosenblum N, Boente MP, Lynch HT, Hamilton TC: Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst. 1996, 88: 1810-20.CrossRefPubMed

14.

Werness BA, Afify AM, Bielat KL, Eltabbakh GH, Piver MS, Paterson JM: Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Hum Pathol. 1999, 30: 151-157.CrossRefPubMed

15.

Barakat RR, Federici MG, Saigo PE, Robson ME, Offit K, Boyd J: Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer. 2000, 89: 383-390. 10.1002/1097-0142(20000715)89:2<383::AID-CNCR25>3.0.CO;2-T.CrossRefPubMed

16.

Sherman ME, Lee JS, Burks RT, Struewing JP, Kurman RJ, Hartge P: Histopathologic features of ovaries at increased risk for carcinoma. A case-control analysis. Int J Gynecol Pathol. 1999, 18: 151-7.CrossRefPubMed

17.

Stratton JF, Buckley CH, Lowe D, Ponder BA: Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. J Natl Cancer Inst. 1999, 91: 626-628. 10.1093/jnci/91.7.626.CrossRefPubMed

18.

Deligdisch L, Gil J, Kerner H, Wu HS, Beck D, Gershoni-Baruch R: Ovarian dysplasia in prophylactic oophorectomy specimens: cytogenetic and morphometric correlations. Cancer. 1999, 86: 1544-1550. 10.1002/(SICI)1097-0142(19991015)86:8<1544::AID-CNCR22>3.3.CO;2-9.CrossRefPubMed

19.

Werness BA, Afify AM, Eltabbakh GH, Huelsman K, Piver MS, Paterson JM: p53, c-erbB, and Ki-67 expression in ovaries removed prophylactically from women with a family history of ovarian cancer. Int J Gynecol Pathol. 1999, 18: 338-343.CrossRefPubMed

20.

Mittal KR, Zeleniuch-Jacquotte A, Cooper JL, Demopoulos RI: Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. Int J Gynecol Pathol. 1993, 12: 59-63.CrossRefPubMed

21.

Resta L, Russo S, Colucci GA, Prat J: Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol. 1993, 82: 181-186.PubMed

22.

Dyck HG, Hamilton TC, Godwin AK, Lynch HT, Maines-Bandiera S, Auersperg N: Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer. Int J Cancer. 1996, 69: 429-436. 10.1002/(SICI)1097-0215(19961220)69:6<429::AID-IJC1>3.0.CO;2-6.CrossRefPubMed

23.

Wong AST, Leung PC, Maines-Bandiera SL, Auersperg N: Metaplastic changes in cultured human ovarian surface epithelium. In Vitro Cell Dev Biol Anim. 1998, 34: 668-70.CrossRefPubMed

24.

Auersperg N, Maines-Bandiera S, Booth JH, Lynch HT, Godwin AK, Hamilton TC: Expression of two mucin antigens in cultured human ovarian surface epithelium: influence of a family history of ovarian cancer. Am J Obstet Gynecol. 1995, 173: 558-565.CrossRefPubMed

25.

Wong AST, Maines-Bandiera SL, Rosen B, Wheelock MJ, Johnson KR, Leung PC, Roskelley CD, Auersperg N: Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: influence of family history of ovarian cancer. Int J Cancer. 1999, 81: 180-8. 10.1002/(SICI)1097-0215(19990412)81:2<180::AID-IJC3>3.3.CO;2-Z.CrossRefPubMed

26.

Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker RS, Bast RC: Growth regulation and transformation of ovarian epithelium. Cancer. 1993, 71: 545-551.CrossRefPubMed

27.

Ziltener HJ, Maines-Bandiera S, Schrader JW, Auersperg N: Secretion of bioactive IL-1, IL-6 and colony stimulating factors by human ovarian surface epithelium. Biol Reprod. 1993, 49: 635-641.CrossRefPubMed

28.

Wong AST, Pelech SL, Woo MM, Yim G, Rosen B, Ehlen T, Leung PC, Auersperg N: Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis?. Oncogene. 2001, 20: 1318-1328. 10.1038/sj.onc.1204253.CrossRefPubMed

29.

Wong AST, Kim SO, Leung PC, Auersperg N, Pelech SL: Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium. Gynecol Oncol. 2001, 82: 305-311. 10.1006/gyno.2001.6280.CrossRefPubMed

30.

Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW: PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999, 21: 99-102. 10.1038/5042.CrossRefPubMed

31.

Kruk PA, Godwin AK, Hamilton TC, Auersperg N: Telomeric instability and reduced proliferative potential in ovarian surface epithelial cells from women with a family history of ovarian cancer. Gynecol Oncol. 1999, 73: 229-36. 10.1006/gyno.1999.5348.CrossRefPubMed

32.

Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW: Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst. 2001, 93: 1458-1464. 10.1093/jnci/93.19.1458.CrossRefPubMed

33.

Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA: Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002, 359: 572-577. 10.1016/S0140-6736(02)07746-2.CrossRefPubMed

34.

Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET: Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst. 2002, 94: 990-1000. 10.1093/jnci/94.13.990.CrossRefPubMed

35.

Hedenfalk IA: Gene expression profiling of hereditary and sporadic ovarian cancer reveals unique BRCA1 and BRCA2 signatures. J Natl Cancer Inst. 2002, 94: 960-961. 10.1093/jnci/94.13.960.CrossRefPubMed

36.

Hilton J, Geisler J, Rathe J, Hattermann-Zogg M, DeYoung B, Buller R: Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst. 2002, 94: 1396-1406. 10.1093/jnci/94.18.1396.CrossRefPubMed

37.

Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, et al.: Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet. 1999, 21: 236-240. 10.1038/6029.CrossRefPubMed

38.

Zheng W, Luo F, Lu JJ, Baltayan A, Press MF, Zhang ZF, Pike MC: Reduction of BRCA1 expression in sporadic ovarian cancer. Gynecol Oncol. 2000, 76: 294-300. 10.1006/gyno.1999.5664.CrossRefPubMed

39.

Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, et al.: Gene-expression profiles in hereditrary breast cancer. N Engl J Med. 2001, 344: 539-548. 10.1056/NEJM200102223440801.CrossRefPubMed

40.

Werness BA, Eltabbakh GH: Familial ovarian cancer and early ovarian cancer: biologic, pathologic, and clinical features. Int J Gynecol Pathol. 2001, 20: 48-63. 10.1097/00004347-200101000-00005.CrossRefPubMed

41.

Shaw PA, McLaughlin JR, Zweemer RP, Narod SA, Risch H, Verheijen RH, Ryan A, Menko FH, Kenemans P, Jacobs IJ: Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol. 2002, 21: 407-411. 10.1097/00004347-200210000-00011.CrossRefPubMed

42.

Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, Seal S, Hamoudi R, van Rensburg EJ, Dunning AM, et al.: Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet. 1995, 11: 428-433.CrossRefPubMed

43.

Johnson NC, Kruk PA: BRCA1 Zinc RING Finger Domain Disruption Alters Caspase Response in Ovarian Surface Epithelial Cells. Cancer Cell Int. 2002, 2: 7-10.1186/1475-2867-2-7.PubMedCentralCrossRefPubMed

44.

Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, Stratton MR, Easton D: Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997, 15: 103-5.CrossRefPubMed

45.

Phelan CM, Rebbeck TR, Weber BL, Devilee P, Ruttledge MH, Lynch HT, Lenoir GM, Stratton MR, Easton DF, Ponder BA, et al.: Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet. 1996, 12: 309-11.CrossRefPubMed

46.

Weitzel JN, Ding S, Larson GP, Nelson RA, Goodman A, Grendys EC, Ball HG, Krontiris TG: The HRAS1 minisatellite locus and risk of ovarian cancer. Cancer Res. 2000, 60: 259-261.PubMed

47.

Narod SA: Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer. 2002, 2: 113-123. 10.1038/nrc726.CrossRefPubMed

48.

Liede A, Narod SA: Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2. Hum Mutat. 2002, 20: 413-424. 10.1002/humu.10154.CrossRefPubMed

49.

Ganesan S, Silver DP, Greenberg RA, Avni D, Drapkin R, Miron A, Mok SC, Randrianarison V, Brodie S, Salstrom J, et al.: BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell. 2002, 111: 393-405.CrossRefPubMed

50.

Buller RE, Sood AK, Lallas T, Buekers T, Skilling JS: Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. J Natl Cancer Inst. 1999, 91: 339-346. 10.1093/jnci/91.4.339.CrossRefPubMed

51.

Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, et al.: Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene. 2001, 20: 77-87. 10.1038/sj.onc.1204073.CrossRefPubMed

52.

Zheng L, Annab LA, Afshari CA, Lee WH, Boyer TG: BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci U S A. 2001, 98: 9587-92. 10.1073/pnas.171174298.PubMedCentralCrossRefPubMed

53.

Liehr JG: Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development. Hum Reprod Update. 2001, 7: 273-81. 10.1093/humupd/7.3.273.CrossRefPubMed

54.

Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, Stallcup MR, Press MF, Coetzee GA: Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res. 2000, 60: 5946-5949.PubMed

55.

Levine DA, Boyd J: The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series. Cancer Res. 2001, 61: 908-911.PubMed

56.

Brodie SG, Deng CX: BRCA1-associated tumorigenesis: what have we learned from knockout mice?. Trends Genet. 2001, 17: S18-22. 10.1016/S0168-9525(01)02451-9.CrossRefPubMed

57.

Bennett LM, McAllister KA, Malphurs J, Ward T, Collins NK, Seely JC, Gowen LC, Koller BH, Davis BJ, Wiseman RW: Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol. Cancer Res. 2000, 60: 3461-3469.PubMed

58.

Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A, Deng CX: Conditional mutation of BRCA1 in mammary epithelial cells results in blunted ductal morphogenesis and tumor formation. Nat Genet. 2001, 22: 37-43.

Title: Ovarian surface epithelium: family history and early events in ovarian cancer
Authors: Alice ST Wong
Nelly Auersperg
Publication date: 01-12-2003
Publisher: BioMed Central
Published in: Reproductive Biology and Endocrinology / Issue 1/2003
Electronic ISSN: 1477-7827
DOI: https://doi.org/10.1186/1477-7827-1-70

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ovarian surface epithelium: family history and early events in ovarian cancer

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2003

Thrombophilia and pregnancy

The expression of cyclin-dependent kinase inhibitors p15, p16, p21, and p27 during ovarian follicle growth initiation in the mouse

Regulation of Akt expression and phosphorylation by 17β-estradiol in the rat uterus during estrous cycle

Mitogen-activated protein kinases in normal and (pre)neoplastic ovarian surface epithelium

IL-11 and IL-11Rα immunolocalisation at primate implantation sites supports a role for IL-11 in placentation and fetal development

4-Aminopyridine Decreases Progesterone Production by Porcine Granulosa Cells